Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases

Retina

Volumn 23, Issue 6, 2003, Pages 764-770

  Enaida, Hiroshi ^a   Hata, Yasuaki ^a   Ueno, Akifumi ^a   Nakamura, Takao ^a   Hisatomi, Toshio ^a   Miyazaki, Miho ^a   Fujisawa, Kimihiko ^a   Sakamoto, Taiji ^a   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Advantages and complications; Triamcinolone acetonide; Triamcinolone acetonide assisted pars plana vitrectomy; Vitrectomy; Vitreoretinal disease

Indexed keywords

TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CILIARY DISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PROLIFERATIVE RETINOPATHY; REOPERATION; RETINA DISEASE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VISION; VITRECTOMY;

AGED; COMBINED MODALITY THERAPY; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETINAL DISEASES; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITRECTOMY;

EID: 0347361621     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200312000-00003     Document Type: Article

References (32)

1. Glaser BM. Surgery of proliferative vitreoretinopathy. In: Ryan SJ, ed. Retina, 2nd ed. St. Louis: CV Mosby, 1994:2265-2280.
2. Smiddy WE, Flynn HW. Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol 1999;43:491-507.
3. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-2104.
4. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979;278:456-459.
5. Hatchell DL, McAdoo T, Sheta S, et al. Quantification of cellular proliferation in experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998;106:669-672.
6. Hui YN, Liang HC, Cai YS, et al. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol 1993;231:109-114.
7. Hui YN, Hu D. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease. Graefe Arch Clin Exp Ophthalmol 1999;237:601-605.
8. Martidis A, Miller DG, Ciulla TA, et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocular Pharm Ther 1999;15:425-428.
9. Tano Y, Chandler DB, McCuen BW, et al. Glucocorticosteroid inhibition of intraocular proliferation after injury. Am J Ophthalmol 1981;91:184-189.
10. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980;90:810-816.
11. Croasdale CR, Brightbill FS. Subconjunctival corticosteroid injections for nonnecrotizing anterior scleritis. Arch Ophthalmol 1999;117:966-968.
12. Gould ES, Bird AC, Leaver PK, et al. Treatment of optic neuritis by retrobulbar injection of triamcinolone. BMJ 1977;1:1495-1497.
13. Jennings T, Rusin MM, Tessler HH, et al. Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol 1988;32:385-391.
14. Lafranco Dafflon M, Tran VT, Guex-Crosier Y, et al. Posterior sub-Tenon's steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol 1999;237:289-295.
15. Riordan-Eva P, Lightman S. Orbital floor steroid injections in the treatment of uveitis. Eye 1994;8:66-69.
16. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol 1998;26:277-281.
17. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
18. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000;84:1064-1067.
19. Jonas JB, Hayler JK, Sofker A, et al. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468-471.
20. Peyman GA, Cheema R, Conway MD, et al. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina 2000;20:554-555.
21. Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the post-operative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 2002;240:423-429.
22. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999;27:431-432.
23. Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-195.
24. Enaida H, Sakamoto T, Ueno A, et al. Submacular deposition of triamcinolone acetonide after triamcinolone-assisted vitrectomy. Am J Ophthalmol 2003;135:243-246.
25. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 1992;36:373-384.
26. Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 1987;94:327-332.
27. Schindler RH, Chandler D, Thresher R, et al. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982;93:415-417.
28. Scholes GN, O'Brien WJ, Abrams GW, et al. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985;103:1567-1569.
29. Ishibashi T, Miki K, Sorgente N, et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985;103:708-711.
30. McCuen BW II, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-788.
31. Ueno A, Enaida H, Hata Y, et al. Triamcinolone-assisted visualization of the residual posterior hyaloid membrane on the detached retina from highly myopic macular hole. Br J Ophthalmol, in press.
32. Sonoda KH, Enaida H, Ueno A, et al. Pars plana vitrectomy assisted by triamcinolone-acetonide for refractory uveitis: a case series study. Br J Ophthalmol, in press.